These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26575470)

  • 1. Transvaginal mesh in the media following the 2011 US food and drug administration public health notification update.
    Koo K; Gormley EA
    Neurourol Urodyn; 2017 Feb; 36(2):329-332. PubMed ID: 26575470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inaccuracies in News Media Reporting About the 2019 US Food and Drug Administration Ban on Transvaginal Mesh for Pelvic Organ Prolapse Repair.
    Ray S; Clifton MM; Koo K
    Urology; 2021 Apr; 150():194-200. PubMed ID: 32439554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Media coverage of the 2019 United States Food and Drug Administration ordered withdrawal of vaginal mesh products for pelvic organ prolapse.
    Shoureshi PS; Lee W; Kobashi KC; Sajadi KP
    Int Urogynecol J; 2021 Feb; 32(2):375-379. PubMed ID: 32601782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic mesh complications in women before and after the 2011 FDA public health notification.
    Rice NT; Hu Y; Slaughter JC; Ward RM
    Female Pelvic Med Reconstr Surg; 2013; 19(6):333-8. PubMed ID: 24165446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midurethral slings: evidence-based medicine vs the medicolegal system.
    Nager CW
    Am J Obstet Gynecol; 2016 Jun; 214(6):708.e1-5. PubMed ID: 27105683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in internet search activity, media coverage, and patient-centered health information after the FDA safety communications on surgical mesh for pelvic organ prolapse.
    Stone BV; Forde JC; Levit VB; Lee RK; Te AE; Chughtai B
    Int Urogynecol J; 2016 Nov; 27(11):1761-1766. PubMed ID: 27209310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Placement and Removal or Revision of Transvaginal Mesh for Pelvic Organ Prolapse and Stress Urinary Incontinence in the Ambulatory Setting before and after the 2011 Food and Drug Administration Notification.
    Polland A; Meckel K; Trop CS
    Urol Pract; 2015 Jul; 2(4):160-164. PubMed ID: 37559260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transvaginal mesh: a historical review and update of the current state of affairs in the United States.
    Iyer S; Botros SM
    Int Urogynecol J; 2017 Apr; 28(4):527-535. PubMed ID: 27549225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 2011 FDA transvaginal mesh safety update on AUGS members' use of synthetic mesh and biologic grafts in pelvic reconstructive surgery.
    Clemons JL; Weinstein M; Guess MK; Alperin M; Moalli P; Gregory WT; Lukacz ES; Sung VW; Chen BH; Bradley CS;
    Female Pelvic Med Reconstr Surg; 2013; 19(4):191-8. PubMed ID: 23797515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transvaginal mesh kits--how "serious" are the complications and are they reversible?
    Lee D; Dillon B; Lemack G; Gomelsky A; Zimmern P
    Urology; 2013 Jan; 81(1):43-8. PubMed ID: 23200966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year surgical complications and mesh erosion of transvaginal Elevate™ mesh for management of pelvic organ prolapse.
    Daniel W; Valerie T; Alan L
    J Obstet Gynaecol; 2022 Aug; 42(6):2354-2359. PubMed ID: 35503566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the FDA statement on transvaginal placement of mesh: the aftermath.
    Koski ME; Rovner ES
    Curr Urol Rep; 2014 Feb; 15(2):380. PubMed ID: 24384996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval process for devices and mesh for surgical treatment of pelvic organ prolapse and urinary incontinence.
    Nygaard I
    Clin Obstet Gynecol; 2013 Jun; 56(2):229-31. PubMed ID: 23632639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Surgical Outcomes and Determinants of Litigation Among Women With Transvaginal Mesh Complications.
    Zoorob D; Karram M; Stecher A; Maxwell R; Whiteside J
    Female Pelvic Med Reconstr Surg; 2016; 22(6):404-409. PubMed ID: 27636217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Implications of the FDA statement on transvaginal placement of mesh: the aftermath.
    Wein AJ
    J Urol; 2015 Feb; 193(2):606-7. PubMed ID: 25617282
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of vaginal mesh in the face of recent FDA warnings and litigation.
    Mucowski SJ; Jurnalov C; Phelps JY
    Am J Obstet Gynecol; 2010 Aug; 203(2):103.e1-4. PubMed ID: 20227672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New considerations in the use of vaginal mesh for prolapse repair.
    Rardin CR; Washington BB
    J Minim Invasive Gynecol; 2009; 16(3):360-4. PubMed ID: 19423069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicolegal issues surrounding devices and mesh for surgical treatment of prolapse and incontinence.
    Nosti PA; Iglesia CB
    Clin Obstet Gynecol; 2013 Jun; 56(2):221-8. PubMed ID: 23563873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in utilization of transvaginal mesh.
    Kohli N
    Curr Opin Obstet Gynecol; 2012 Oct; 24(5):337-42. PubMed ID: 22954765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolapse Recurrence after Transvaginal Mesh Removal.
    Rawlings T; Lavelle RS; Coskun B; Alhalabi F; Zimmern PE
    J Urol; 2015 Nov; 194(5):1342-7. PubMed ID: 26119669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.